Dr. Xin Yao
Claim this profileThedaCare Regional Cancer Center
Studies Colorectal Cancer
Studies Adenocarcinoma
13 reported clinical trials
27 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
dMMR negative
2Adenocarcinoma
Stage IV
dMMR negative
MSI-H negative
Affiliated Hospitals
Clinical Trials Xin Yao is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
More about Xin Yao
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Xin Yao has experience with
- Nivolumab
- Fluorouracil
- Leucovorin Calcium
- Bevacizumab
- Ipilimumab
- Carboplatin
Breakdown of trials Xin Yao has run
Colorectal Cancer
Adenocarcinoma
Prostate Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Xin Yao specialize in?
Xin Yao focuses on Colorectal Cancer and Adenocarcinoma. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Xin Yao currently recruiting for clinical trials?
Yes, Xin Yao is currently recruiting for 5 clinical trials in Appleton Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Xin Yao has studied deeply?
Yes, Xin Yao has studied treatments such as Nivolumab, Fluorouracil, Leucovorin Calcium.
What is the best way to schedule an appointment with Xin Yao?
Apply for one of the trials that Xin Yao is conducting.
What is the office address of Xin Yao?
The office of Xin Yao is located at: ThedaCare Regional Cancer Center, Appleton, Wisconsin 54911 United States. This is the address for their practice at the ThedaCare Regional Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.